| Lonza Group AG | 671.1300 / +3.43% |
News
- Capricor Collaborates with Lonza for the Development of CAP-1002, its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications
01/12/2021 / 15:05 - GlobeNewswire - Achilles Therapeutics Appoints Arjan Roozen as VP, Site Head and General Manager
01/08/2021 / 13:00 - GlobeNewswire - Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal
12/23/2020 / 14:00 - GlobeNewswire - Altimmune Adds Lonza as a Manufacturing Partner for Supply of AdCOVID™ its Single-Dose Intranasal Vaccine Candidate for COVID-19
11/10/2020 / 07:00 - GlobeNewswire - Institutional Investor Research Publishes 2020 Europe Executive Team Rankings
09/04/2020 / 07:00 - GlobeNewswire - Amarantus Announces Subsidiary MANF Therapeutics Enters Into Material Transfer Agreement with Dyadic International
02/06/2020 / 14:11 - GlobeNewswire - Amarantus Releases Letter to Shareholders
02/04/2020 / 15:54 - GlobeNewswire - Amarantus Acquires Majority Interest in CBD Wellness Company Hempori
01/30/2020 / 15:05 - GlobeNewswire - Amarantus Completes Sublicense of ESS, MANF and PhenoGuard to Emerald Organic Products
01/02/2020 / 14:14 - GlobeNewswire - Amarantus to Present at 12th Annual LD Micro Main Event
12/09/2019 / 14:00 - GlobeNewswire - Amarantus Subsidiary Elto Pharma Receives Notice of Allowance Covering Use of Eltoprazine Combined with CBD to Treat Parkinson’s Disease
12/04/2019 / 13:36 - GlobeNewswire - Amarantus Announces Issuance of Chinese Patent Covering the Use of MANF and CDNF in Retinal Disorders for Subsidiary MANF Therapeutics
11/21/2019 / 14:00 - GlobeNewswire - Amarantus Provides Recapitalization Update to Shareholders
11/18/2019 / 14:30 - GlobeNewswire - Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET
11/14/2019 / 17:02 - GlobeNewswire - Global Primary Cells Market Analysis, Trends, and Forecasts Report 2019
10/30/2019 / 11:17 - GlobeNewswire
Real-time